GlobeNewswire by notified

CDL’s global network expands with new CDL-Berlin site, with a focus on ventures massively impacting life sciences

Share

Hosted by ESMT Berlin, Germany’s No. 1 business school, CDL’s newest site is where Europe’s most vibrant startup landscape intersects with a world-class life-science research ecosystem

Toronto, Ontario, Canada; Berlin, Germany, June 23, 2022 (GLOBE NEWSWIRE) -- BERLIN/TORONTO — Creative Destruction Lab (CDL), founded at the Rotman School of Management at the University of Toronto, is launching a new site and program stream in Berlin, Germany’s most vibrant startup ecosystem. CDL-Berlin aims to massively improve personal and planetary health by engaging founders working at the leading edge of life sciences.

The new Health stream at ESMT Berlin will integrate CDL’s worldwide network of mentors, investors and entrepreneurs with Germany’s globally renowned health care and research systems. This stream will focus on translational science and technology innovations that improve human health and wellness, including digital health, medical devices, diagnostics, bioinformatics, genomics, as well as biotechnologies including therapeutics and synthetic biology.

CDL delivers an objectives-based, nine-month mentorship program for massively scalable science- and tech-based startups. CDL-Berlin will bridge the current commercialization gap in Europe between ​​scientific excellence and entrepreneurial translation. ​​

Germany is known for outstanding research across all technological sectors, but has lacked in transferring technologies into ambitious ventures and ultimately new global champions. The country is now building a new generation of deep tech entrepreneurs that leverage the power of top-notch research to address the world’s most pressing societal and environmental problems. In life science research and early discovery, Europe’s direct annual global potential impact is estimated at $0.5 trillion to $1.3 trillion over the next 10 to 20 years. 

CDL-Berlin will unleash this potential and significantly improve the lab-to-market timeline, as well as success rates, by supporting founders on their market access, regulatory and business challenges.

“CDL is a great addition to our entrepreneurship and tech portfolio at ESMT and will give our students who are interested in founding access to an experiential program and opportunities for hands-on experience. In cooperation with world-class health institutions based in Berlin, we would like to make a lasting impact within the thriving health care ecosystem,” said Jörg Rocholl, President, ESMT. 

“We are very pleased to have won over Thorsten Lambertus, with his strong expertise in deep tech innovation, to lead our CDL site, and look forward to announcing a renowned academic director in the near future,” Rocholl added.

ESMT Berlin is at the heart of Europe, and is the ideal home for this new CDL site. ESMT is Germany’s No. 1 business school, developing entrepreneurial leaders who think globally, and act responsibly. As an institution that’s embedded in Germany’s deep tech economy, ESMT holds close ties with top-tier research institutions, world-leading companies, and hidden champions across all sectors. 

With the Health stream, CDL-Berlin focuses on an industry with a major recent success case: BioNTech. CDL-Berlin will contribute to global efforts in improving human health and wellness, and is situated to give founders access to a world-renowned center of medical excellence. It is home to several leading institutions and programs with a strong focus on health care, including: 

  • Charité, the fifth-best hospital worldwide and a leading hospital in Europe.
  • A health care ecosystem ranked No. 3 in the World Index of Healthcare Innovation in 2021 (Foundation for Research on Equal Opportunity).
  • The yearly World Health Summit, bringing together experts from academia, industry, and politics.
  • Eight life science technology parks, approximately 40 research facilities focusing on life sciences, and 170 health-related programs of study (Life Science Report Berlin 2019/2020).

“CDL is a structured social experience with economic impact. The program has a proven process for helping companies cut through distractions and focus on what’s most important,” says Sonia Sennik, executive director of CDL. “We are delighted to welcome Berlin’s vibrant community of seasoned entrepreneurs and experienced investors to the global CDL network.” 

“Germany is an innovation powerhouse with outstanding research across all technological sectors, but innovators struggle to transfer technologies into ambitious and ultimately successful ventures,” said Marco Janezic, founding partner of Blue Ribbon Partners, a company builder focusing on life sciences, and seasoned mentor at CDL-Oxford. “CDL-Berlin is well placed at Germany’s top business school ESMT to fill this gap.”

Companies and founders interested in applying to the CDL-Berlin Health stream can contact cdl-berlin@creativedestructionlab.com for more information. Join a CDL Health Webinar to learn more. Applications will be accepted online until August 31, 2022.

About Creative Destruction Lab

Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. Its nine-month program allows founders to learn from experienced entrepreneurs, increasing their likelihood of success. Founded in 2012 by Professor Ajay Agrawal at the University of Toronto’s Rotman School of Management, the program has expanded to 12 sites across six countries. Participating ventures have created $20 billion (CAD) in equity value. https://creativedestructionlab.com/

About ESMT Berlin

ESMT Berlin is the highest ranked business school in Germany and top 10 in Europe. Founded by 25 leading global companies, ESMT offers master’s, MBA, and PhD programs, as well as executive education on its campus in Berlin, in locations around the world, online, and in online blended format. Focusing on leadership, innovation, and analytics, its diverse faculty publishes outstanding research in top academic journals. Additionally, the international business school provides an interdisciplinary platform for discourse between politics, business, and academia. ESMT is a non-profit private institution of higher education, accredited by AACSB, AMBA, EQUIS, and FIBAA, and is committed to diversity, equity, and inclusion across all its activities and communities. https://esmt.berlin/

Media Contact

Amarpreet Kaur
Associate Director
Creative Destruction Lab
amarpreet.kaur@creativedestructionlab.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Fingerprints announces design win for its optical under-display solution with major Asian smartphone OEM30.6.2022 08:00:00 CEST | Press release

Fingerprint Cards AB (Fingerprints™) today announced that it has secured a design win* for its optical under-display solution, FPC 1632, with a major Asian smartphone OEM, following successful qualification tests earlier this year. We expect to commence shipments during the fourth quarter of 2022. “Since many years, Fingerprints is a well-established world leader in capacitive fingerprint sensors. The design win we are announcing today marks our entry into a new market segment: optical under-display fingerprint sensors. This will open up attractive new growth opportunities for us going forward, and our goal is to capture a significant share of this market,” says Ted Hansson, President Mobile, PC & Access China at Fingerprints. For more information about Fingerprints’ mobile device solutions, visit the website. * Fingerprints’ definition of Design Win (DW): The decision by a device vendor (OEM or ODM) to start development of one or several commercial product(s) incorporating Fingerprint

Inaugural Yara Clean Ammonia Capital Markets Day30.6.2022 08:00:00 CEST | Press release

Oslo, 30 June 2022: Today, Yara International ASA (“Yara”) will host a Capital Markets Day (“CMD”) for Yara Clean Ammonia (“YCA” or the “Company”). During the event, members of YCA’s management team will present key features of the Company, including its strategy and growth ambitions, as well as financial parameters and targets for the future. In May 2022, Yara announced that it is evaluating a potential initial public offering (“IPO”) of YCA on the Oslo Stock Exchange. “While the decision to list YCA will be made in due course, Yara is now excited to host an inaugural CMD for YCA to showcase their exciting story,” said Svein Tore Holsether, CEO and President of Yara. “YCA combines a leading midstream business with exceptional growth prospects and a value creating project portfolio.” Key highlights: Clean ammonia represents a massive opportunity that is projected to drive exponential, long-term market growth [1].YCA comprises existing cash flows from a market leading position [2] in a

Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma30.6.2022 08:00:00 CEST | Press release

Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 monthsStudy provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces the completed recruitment of 154 patients in the INITIUM trial. INITIUM is Ultimovacs’ Phase II clinical trial of its universal cancer vaccine UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab in metastatic malignant melanoma. Consistent with INITIUM’s event-driven design, topline progression-free survival results will be disclosed after progression of cancer or death has been observed in a total of 70 patients. “It is a remarkable achievement that Ultimovacs and its clinical partners have completed recruitment to INITIUM largely on schedule despite challenges caused by the pandemic,” said Carlos de Sou

Sampo plc’s share buybacks 29/06/202230.6.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 30/06/2022 at 08:30 am Sampo plc’s share buybacks 29/06/2022 On 29/06/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,37741.79AQEU49,88741.79CEUX8,78241.76TQEX102,19541.79XHELTOTAL175,24141.79 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 2,017,160 Sampo A shares representing 0.38 per cent of the total number of shares in Sampo plc. Details of e

Millicom increases Tigo Panama ownership to 100%29.6.2022 23:36:16 CEST | Press release

Millicom increases Tigo Panamaownership to 100% Luxembourg, June 29, 2022 – Millicom closed today the previously-announced transaction to acquire the remaining 20% interest in Telecomunicaciones Digitales, S.A. (formerly known as Cable Onda S.A. or “Tigo Panama”) reflecting an exercise of the founders’ liquidity option as provided for in the Shareholders’ Agreement, which was entered into in 2018. As a result, Millicom now owns 100% of Tigo Panama, the leader in Panama’s telecommunications market. For further information, please contact: Press: Yocasta Valdez, Sr. Manager Digital Media & Communications press@millicom.com Investors: Michel Morin, VP Investor Relations Sarah Inmon, Director Investor Relations investors@millicom.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of fixed and mobile telecommunications services in Latin America. Through our TIGO® and Tigo Business® brands, we provide a wide range of digital services and product